New Delhi: India's leading biotech firm Biocon Monday said it would launch in the next three-four years a new anti-arthritis drug which would have the potential to "be a multi-billion dollar opportunity for the company".
"The new molecule (T1H) which has completed phase II of clinical trials can prove to be a multi-billion opportunity for us," said Kiran Mazumdar Shaw, chairman and managing director of Biocon Ltd, on the sidelines of the 22nd Indian Economic Summit here.
"Phase III of the trails will start within the next 18 months and for that we are looking at global partners," she added.
The company is also looking at earning revenue of about $100 million from the recent cancer drug BIOMAb-EGFR, mainly from the Middle East market.
Biocon launched BIOMAb-EGFR last month for treating solid tumours of epithelial origin, such as head and neck cancers.